Efficacy of Combined Treatment With CoQ10 and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02315651|
Recruitment Status : Unknown
Verified October 2014 by Rabin Medical Center.
Recruitment status was: Not yet recruiting
First Posted : December 12, 2014
Last Update Posted : December 12, 2014
|Condition or disease||Intervention/treatment||Phase|
|Attention Deficit Hyperactivity Disorder||Dietary Supplement: Coenzyme Q10 Dietary Supplement: Placebo||Not Applicable|
The aim of this study is to evaluate the effects of nutritional supplement co-enzyme Q10 (CoQ10) on methylphenidate-treated ADHD children in a randomized, double-blinded, placebo-controlled prospective study. All eligible patients will undergo randomization and divided into 2 groups: a CoQ10-enriched snack and a placebo snack group. According to power calculation, total of 60 subjects are expected to participate in the study. After the screening of eligibility (up to 14 days), the study is divided into three phases: pre-treatment (first assessment) phase (up to 14 days), treatment phase 8 weeks of treatment, and post-treatment phase. Screening: each participant will undergo screening for protocol eligibility within 14 days (two weeks) of recruitment. Subjects who meet all the inclusion criteria and signed an approved informed consent (both parents and the child) will be enrolled.
Pre-treatment period (1-st phase): for the purpose of the first assessment, participants' parents will receive Conner's questionnaire for filling by parents and teachers. The first nutritional assessment will be undertaken using 24-h recall assessment.
Treatment period (2-st phase): randomization and treatment. After randomization to 2 groups, CoQ10 and placebo groups, the participants' parents will receive either CoQ10-enriched or placebo snack for 8 weeks (2 months) period. The participants and their parents will be instructed to consume the snack daily. During the study the subjects will manage with their methylphenidate treatment as indicated by their neurologist.
Post-treatment assessment (3-rd phase): At the end of the study period, an additional assessment identical to this of the pre-treatment will be taken to evaluate subjects' response to the snacks.
Statistical analysis (4-th phase): At the end of the study, statistical analysis will be undertaken. Statistical difference between two groups in their pre-treatment and post-treatment behavioral and nutritional response will serve as an evidence for the efficacy of the supplement being used. All data will be documented in patient charts and individual computerized case report form .
The duration of the study is expected to be 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Primary Purpose:||Supportive Care|
|Official Title:||Efficacy of Combined Treatment With Co-enzyme Q10 and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder|
|Study Start Date :||January 2015|
|Estimated Primary Completion Date :||November 2015|
|Estimated Study Completion Date :||November 2016|
Experimental: Coenzyme Q10
30 children aged 6-12 will consume daily a snack containing 60 mg of CoQ10 for 8 weeks.
Dietary Supplement: Coenzyme Q10
A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
Placebo Comparator: Placebo
30 children aged 6-12 years will consume an identical snack without CoQ10 for 8 weeks
Dietary Supplement: Placebo
A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
- Evaluation of an effect of coenzyme CoQ10 on behavioral aspects of methylphenidate- treated ADHD children [ Time Frame: 60 days ]The evaluation will be executed with Conners score
- Evaluation of an effect of coenzyme Q10 on nutritional behavior of methylphenidate- treated ADHD children [ Time Frame: 60 days ]The evaluation will be executed with 24-h recall and measuring of BMI
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02315651
|Contact: Rachel Straussberg, Prof.||firstname.lastname@example.org|
|Schneider children's medical center of Israel|
|Principal Investigator:||Rachel Straussberg, Prof.||Schneider children's medical center of Israe|